The Biostatistics Core provides statistical collaboration and data management support for each of the SPORE projects, the developmental projects, and the other Cores. In this competitive renewal, the Biostatistics Core has been very active in preparing the statistical plan for each Project. In addition, the Biostatistics Core continues to provide data management for each of the projects, adverse event monitoring for the clinical trials, and prepares data summaries for manuscript preparation. These projects span a wide range of approaches and analyses. The Biostatistics Core builds upon the innovative and time-tested procedures and systems developed by Mayo Clinic, one of the largest statistical groups in the country whose members have collaborated on clinical and basic science research studies since 1932. The Biostatistics Core will provide statistical support across different fields, including epidemiological studies, basic sciences including translational and immunologic correlative studies, gene expression and imaging, clinical trials, gene and mutation discovery, next generation sequencing and information management. The comprehensive nature of the Biostatistics Core assures each SPORE investigator access to statistical expertise that includes collaborative development of study designs and analysis plans, state of the art data analysis and interpretation, data management resources, and abstract and manuscript preparation. The Biostatistics Core also provides a mechanism for the management and integration of both existing and newly collected data through consistent and compatible data handling, database development, data form development and processing, data collection and entry, data archiving, quality control, and management of information relating to the projects and cores. This Core complements and assists the efforts of the Clinical Research and Tissue Cores by providing superior data management and experience with tissue registries. The strengths of the Biostatistics Core are our collaboration with each of the projects and cores, the ability to utilize the established centralized research database as well as the operational and statistical infrastructure already in place in the SPORE, and the breadth of expertise provided by Biostatistics Core personnel.

Public Health Relevance

The Biostatistics Core collaborates with SPORE investigators in designing studies and clinical trials, determining optimal data collection methods, performing data management and quality control, and in analyzing and interpreting study results. The Biostatistics Core interacts with the Clinical Research and Tissue Cores, ensuring optimal use of resources and outstanding quality research with the utmost reliability.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA102701-11A1
Application #
8738916
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2014-09-18
Project End
2019-08-31
Budget Start
2014-09-18
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
$282,919
Indirect Cost
$104,240
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wolf, Susan M; Scholtes, Emily; Koenig, Barbara A et al. (2018) Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. J Law Med Ethics 46:87-109
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Hu, Chunling; Hart, Steven N; Polley, Eric C et al. (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319:2401-2409

Showing the most recent 10 out of 336 publications